Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.65 |
| ▸ | PIM1 | P11309 | 1/20 | 0.65 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.65 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2294360 | 0.90 | CHEK1 (0.57) | CHEK1PIM1MAPK8CLK4MEN1 | |
| SCHEMBL2292384 | 0.86 | MEN1 (0.63) | CHEK1PIM1MAPK8CLK4MEN1 | |
| SCHEMBL2291665 | 0.86 | CHEK1 (0.60) | CHEK1PIM1MAPK8CLK4MEN1 | |
| SCHEMBL2291837 | 0.84 | CHEK1 (0.58) | CHEK1PIM1MAPK8CLK4MEN1 | |
| SCHEMBL472749 | 0.82 | — | — | |
| SCHEMBL2292518 | 0.81 | SERPINE1 (0.71) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL14227315 | 0.80 | MEN1 (0.66) | CHEK1PIM1MAPK8CLK4MEN1 | |
| SCHEMBL2291001 | 0.80 | NR1H4 (0.62) | CHEK1PIM1MAPK8CLK4MEN1 | |
| SCHEMBL2025586 | 0.80 | MEN1 (0.72) | CHEK1PIM1MAPK8CLK4MEN1 | |
| SCHEMBL30466712 | 0.80 | MEN1 (0.72) | CHEK1PIM1MAPK8CLK4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989657-B2 | Anthranilic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | claimed |
| US-20090247637-A1 | Novel Anthranilic Acid Derivatives | DEHMLOW HENRIETTA | 2009-10-01 | — | — | US | claimed |
| JP-2008546661-A | — | — | 2008-12-25 | — | — | JP | claimed |
| EP-1896396-A1 | ANTHRANILIC ACID DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-03-12 | — | — | EP | claimed |
| WO-2006134040-A1 | ANTHRANILIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-21 | — | — | WO | claimed |
| US-20060281810-A1 | Novel anthranilic acid derivatives | HOFFMANN-LA ROCHE INC. | 2006-12-14 | — | — | US | claimed |
| US-7989657-B2 | Anthranilic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090247637-A1 | Novel Anthranilic Acid Derivatives | DEHMLOW HENRIETTA | 2009-10-01 | — | — | US | disclosed |
| EP-1896396-A1 | ANTHRANILIC ACID DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006134040-A1 | ANTHRANILIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-21 | — | — | WO | disclosed |
| US-20060281810-A1 | Novel anthranilic acid derivatives | HOFFMANN-LA ROCHE INC. | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281810-A1 | Novel anthranilic acid derivatives | GPR84, HCAR1, GPR88 | CHEK1 4126/4885PIM1 4409/4885MAPK8 1419/4885 |
| US-20090247637-A1 | Novel Anthranilic Acid Derivatives | GPR84, GPR88, HCAR1 | CHEK1 4268/4885PIM1 4236/4885MAPK8 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.